Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track MCRB with free AI briefings, catalyst countdowns, and dilution alerts.

MCRB · Seres Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$15.6M Cash on Hand

2.4mo Cash Runway

Follow MCRB by email Get an email when MCRB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MCRB, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jul 2024 · Phase 1 · Results Expected · A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adu
Registry primary completion date, not a results date
Apr 2022 · Phase 3 · Results Expected · ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile I
Registry primary completion date, not a results date
Jul 2020 · Phase 3 · Results Expected · ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium
Registry primary completion date, not a results date
May 2018 · Phase 1 · Results Expected · SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent R
Registry primary completion date, not a results date
Dec 2017 · Phase 1 · Results Expected · A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subject
Registry primary completion date, not a results date
Jul 2016 · Phase 2 · Results Expected · SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
SER-109	Clostridium Difficile Infection	Phase 3 · NCT03183128	Completed
SER-287	Ulcerative Colitis	Phase 2 · NCT03759041	Terminated
Vancomycin Pre-Treatment	Ulcerative Colitis	Phase 2 · NCT03759041	Terminated
Microbiome SER-155	Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1 · NCT04995653	Completed
SER-262	Clostridium Difficile Infection	Phase 1 · NCT02830542	Completed
Microbiome SER-401	Metastatic Melanoma	Phase 1 · NCT03817125	Completed
Vancomycin Pre-Treat	Ulcerative Colitis	Phase 1 · NCT02618187	Completed
Vancomycin pretreatment	Metastatic Melanoma	Phase 1 · NCT03817125	Completed

Also used in these trials (approved or third-party drugs, not MCRB's own candidates): Nivolumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MCRB holds $15.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $19.4M/quarter from operations, an estimated runway of 2.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 62 · High

Cash runway 2 months +40
Going-concern doubt in the latest 10-Q +15The principal risks and uncertainties affecting our business include the following: • We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern. 10-Q, Aug 2026
Share count +14% in a year +7

Recent financing filings on SEC EDGAR:

Oct 1, 2024 · Private placement (8-K Item 3.02) · 8-K
Aug 6, 2024 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MCRB files for a raise →

Get the full MCRB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MCRB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z